TY  - GEN
AU  - Richardson,Paul G
AU  - Schlossman,Robert L
AU  - Weller,Edie
AU  - Hideshima,Teru
AU  - Mitsiades,Constantine
AU  - Davies,Faith
AU  - LeBlanc,Richard
AU  - Catley,Laurence P
AU  - Doss,Deborah
AU  - Kelly,Kathleen
AU  - McKenney,Mary
AU  - Mechlowicz,Julie
AU  - Freeman,Andrea
AU  - Deocampo,Reggie
AU  - Rich,Rebecca
AU  - Ryoo,Joan J
AU  - Chauhan,Dharminder
AU  - Balinski,Kathe
AU  - Zeldis,Jerome
AU  - Anderson,Kenneth C
TI  - Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
SN  - 0006-4971
PY  - 2002///1210
KW  - Adjuvants, Immunologic
KW  - administration & dosage
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Apoptosis
KW  - drug effects
KW  - Combined Modality Therapy
KW  - Constipation
KW  - chemically induced
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Lenalidomide
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Myeloma Proteins
KW  - analysis
KW  - Nervous System Diseases
KW  - Neutropenia
KW  - Peripheral Blood Stem Cell Transplantation
KW  - Remission Induction
KW  - Safety
KW  - Salvage Therapy
KW  - Thalidomide
KW  - Thrombocytopenia
KW  - Transplantation, Autologous
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1182/blood-2002-03-0996
ER  -